Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 42 No. 1
PSYCHOPHARMACOLOGY BULLETIN

VOL 42 No. 1

Articles in This Issue

LETTER TO THE EDITOR

A Case of Stuttering During Treatment with Levomepromazine

Branimir Margetić, Branka Aukst-Margetić, Branko Krajinović
Stuttering is a disturbance in the normal fluency and time patterning of speech, characterized by sound and syllable repetitions, sound prolongations and broken words. Acquired stuttering that begins in adulthood is rather unusual. It might...
Pages 8-10 Read Article
ORIGINAL RESEARCH

Atypical Antipsychotic Drugs and Diabetes Mellitus in the US Food and Drug Administration Adverse Event Database: A Systematic Bayesian Signal Detection Analysis

Ross A. Baker, Andrei Pikalov, Quynh-Van Tran, Tatyana Kremenets, Ramin B. Arani, P. Murali Doraiswamy
Background: Prior literature suggests that the risk of diabetes-related adverse events (DRAEs) differs between atypical antipsychotics. The present study evaluated the potential association between atypical antipsychotics or haloperidol and diabetes using data from the FDA...
Pages 11-30 Read Article
ORIGINAL RESEARCH

Bipolar-I Patient Characteristics Associated with Differences in Antimanic Medication Prescribing

Alisa B. Busch, Richard G. Frank, Gary Sachs, Sharon-Lise T. Normand
Objective: Second-generation antipsychotics offer more choice in antimanic pharmacologic treatment. Unclear though is whether they are expanding antimanic treatment, replacing mood stabilizers, or if/which patient characteristics influence prescribing choices. We studied the association between patient...
Pages 35-49 Read Article
ORIGINAL RESEARCH

Neuropsychological Functioning in Patients with Post Traumatic Stress Disorder Following Short Term Paroxetine Treatment

Negar Fani, Noriyuki Kitayama, Ali Ashraf, Lai Reed, Nadeem Afzal, Farhan Jawed, J. Douglas Bremner
A previous study found improvements in verbal declarative memory in patients with Posttraumatic Stress Disorder (PTSD) following one year of open-label paroxetine treatment. The purpose of the present study was to replicate prior findings and...
Pages 53-68 Read Article
ORIGINAL RESEARCH

An Open-Label Assessment of Aripiprazole in the Treatment of PTSD

Sophie Robert, Mark B. Hamner, Valerie L. Durkalski, Mary W. Brown, Helen G. Ulmer
Background: Recent studies suggest that atypical antipsychotics may be effective augmentation strategies for the treatment of posttraumatic stress disorder (PTSD). Limited data were available on the newest agent, aripiprazole, so we aimed to evaluate its...
Pages 69-80 Read Article
ORIGINAL RESEARCH

Differential Efficacy of Memantine for Obsessive-Compulsive Disorder vs. Generalized Anxiety Disorder: An Open-Label Trial

Jamie D. Feusner, Lauren Kerwin, Sanjaya Saxena, Alexander Bystritsky
Objective: A substantial proportion of patients with obsessive-compulsive disorder (OCD) and generalized anxiety disorder (GAD) do not respond to, or are intolerant of, standard treatments. Additional treatment strategies are therefore necessary. Excessive action of the...
Pages 81-93 Read Article
EVIDENCE-BASED MEDICINE

Early Symptom Change Prediction of Remission in Depression Treatment

Martin M. Katz, Adam L. Meyers, Apurva Prakash, Paula J. Gaynor, John P. Houston
Objectives: This study investigated hypothesized early symptom changes as differential predictors of long-term remission for duloxetine and escitalopram. Experimental Design: This was a post-hoc analysis from a placebo-controlled, randomized, double-blind study of patients with major...
Pages 94-107 Read Article